Potactasol الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

potactasol

actavis group ptc ehf - topotecan - uterine cervical neoplasms; small cell lung carcinoma - antineoplastic agents - topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease. patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1).

TOPOTECAN 4 Mg/Ml Pdr for Soln for Infusion أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

topotecan 4 mg/ml pdr for soln for infusion

fresenius kabi oncology plc - topotecan hydrochloride - pdr for soln for infusion - 4 mg/ml - other antineoplastic agents

TOPOTECAN 4 Milligram Pdr/Conc/Soln for Infus أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

topotecan 4 milligram pdr/conc/soln for infus

accord healthcare limited - topotecan (as hydrochloride) - pdr/conc/soln for infus - 4 milligram

TOPOTECAN EBEWE 1 Mg/Ml Concentrate for Soln for Inf أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

topotecan ebewe 1 mg/ml concentrate for soln for inf

ebewe pharma ges.m.b.h nfg. kg - topotecan hydrochloride - concentrate for soln for inf - 1 mg/ml